Role of MTOR Inhibitors in Kidney Disease

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2016 Jun 25

PMID 27338360

Citations 31

Authors

Moto Kajiwara

Satohiro Masuda

Affiliations

Soon will be listed here.

Abstract

The first compound that inhibited the mammalian target of rapamycin (mTOR), sirolimus (rapamycin) was discovered in the 1970s as a soil bacterium metabolite collected on Easter Island (Rapa Nui). Because sirolimus showed antiproliferative activity, researchers investigated its molecular target and identified the TOR1 and TOR2. The mTOR consists of mTOR complex 1 (mTORC1) and mTORC2. Rapalogues including sirolimus, everolimus, and temsirolimus exert their effect mainly on mTORC1, whereas their inhibitory effect on mTORC2 is mild. To obtain compounds with more potent antiproliferative effects, ATP-competitive inhibitors of mTOR targeting both mTORC1 and mTORC2 have been developed and tested in clinical trials as anticancer drugs. Currently, mTOR inhibitors are used as anticancer drugs against several solid tumors, and immunosuppressive agents for transplantation of various organs. This review discusses the role of mTOR inhibitors in renal disease with a particular focus on renal cancer, diabetic nephropathy, and kidney transplantation.

Citing Articles

mTOR pathway: A key player in diabetic nephropathy progression and therapeutic targets.

Shi J, Liu X, Jiao Y, Tian J, An J, Zou G Genes Dis. 2024; 12(2):101260.

PMID: 39717716 PMC: 11665407. DOI: 10.1016/j.gendis.2024.101260.

Posttransplant complications: molecular mechanisms and therapeutic interventions.

Liu X, Shen J, Yan H, Hu J, Liao G, Liu D MedComm (2020). 2024; 5(9):e669.

PMID: 39224537 PMC: 11366828. DOI: 10.1002/mco2.669.

Unravelling infiltrating T-cell heterogeneity in kidney renal clear cell carcinoma: Integrative single-cell and spatial transcriptomic profiling.

Chen H, Zuo H, Huang J, Liu J, Jiang L, Jiang C J Cell Mol Med. 2024; 28(12):e18403.

PMID: 39031800 PMC: 11190954. DOI: 10.1111/jcmm.18403.

The "Road" to Malignant Transformation from Endometriosis to Endometriosis-Associated Ovarian Cancers (EAOCs): An mTOR-Centred Review.

Hablase R, Kyrou I, Randeva H, Karteris E, Chatterjee J Cancers (Basel). 2024; 16(11).

PMID: 38893278 PMC: 11172073. DOI: 10.3390/cancers16112160.

Artesunate Alleviates Kidney Fibrosis in Type 1 Diabetes with Periodontitis Rats via Promoting Autophagy and Suppression of Inflammation.

Liang C, Ma L, Chen Y, Li J, Wang B, Ma C ACS Omega. 2024; 9(14):16358-16373.

PMID: 38617690 PMC: 11007779. DOI: 10.1021/acsomega.4c00020.

References

Moscarelli L, Caroti L, Antognoli G, Zanazzi M, Di Maria L, Carta P . Everolimus leads to a lower risk of BKV viremia than mycophenolic acid in de novo renal transplantation patients: a single-center experience. Clin Transplant. 2013; 27(4):546-54. DOI: 10.1111/ctr.12151. View

Naesens M, Kuypers D, Sarwal M . Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol. 2009; 4(2):481-508. DOI: 10.2215/CJN.04800908. View

Lloberas N, Cruzado J, Franquesa M, Herrero-Fresneda I, Torras J, Alperovich G . Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats. J Am Soc Nephrol. 2006; 17(5):1395-404. DOI: 10.1681/ASN.2005050549. View

Heitman J, Movva N, Hall M . Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science. 1991; 253(5022):905-9. DOI: 10.1126/science.1715094. View

Stallone G, Infante B, Schena A, Battaglia M, Ditonno P, Loverre A . Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients. J Am Soc Nephrol. 2005; 16(12):3755-62. DOI: 10.1681/ASN.2005060635. View

Hay N, Sonenberg N . Upstream and downstream of mTOR. Genes Dev. 2004; 18(16):1926-45. DOI: 10.1101/gad.1212704. View

Rosner M, Freilinger A, Hengstschlager M . Akt regulates nuclear/cytoplasmic localization of tuberin. Oncogene. 2006; 26(4):521-31. DOI: 10.1038/sj.onc.1209812. View

Chan H, Grossman A, Bukowski R . Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors. Adv Ther. 2010; 27(8):495-511. DOI: 10.1007/s12325-010-0045-2. View

Choueiri T, Escudier B, Powles T, Mainwaring P, Rini B, Donskov F . Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373(19):1814-23. PMC: 5024539. DOI: 10.1056/NEJMoa1510016. View

10.

Mizushima N, Yoshimori T, Levine B . Methods in mammalian autophagy research. Cell. 2010; 140(3):313-26. PMC: 2852113. DOI: 10.1016/j.cell.2010.01.028. View

11.

Sarbassov D, Ali S, Sengupta S, Sheen J, Hsu P, Bagley A . Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell. 2006; 22(2):159-68. DOI: 10.1016/j.molcel.2006.03.029. View

12.

Grenda R, Watson A, Trompeter R, Tonshoff B, Jaray J, Fitzpatrick M . A randomized trial to assess the impact of early steroid withdrawal on growth in pediatric renal transplantation: the TWIST study. Am J Transplant. 2010; 10(4):828-836. DOI: 10.1111/j.1600-6143.2010.03047.x. View

13.

Clippinger A, Maguire T, Alwine J . The changing role of mTOR kinase in the maintenance of protein synthesis during human cytomegalovirus infection. J Virol. 2011; 85(8):3930-9. PMC: 3126115. DOI: 10.1128/JVI.01913-10. View

14.

Benjamin D, Colombi M, Moroni C, Hall M . Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov. 2011; 10(11):868-80. DOI: 10.1038/nrd3531. View

15.

Liacini A, Seamone M, Muruve D, Tibbles L . Anti-BK virus mechanisms of sirolimus and leflunomide alone and in combination: toward a new therapy for BK virus infection. Transplantation. 2010; 90(12):1450-7. DOI: 10.1097/TP.0b013e3182007be2. View

16.

Masoud G, Li W . HIF-1α pathway: role, regulation and intervention for cancer therapy. Acta Pharm Sin B. 2015; 5(5):378-89. PMC: 4629436. DOI: 10.1016/j.apsb.2015.05.007. View

17.

Godel M, Hartleben B, Herbach N, Liu S, Zschiedrich S, Lu S . Role of mTOR in podocyte function and diabetic nephropathy in humans and mice. J Clin Invest. 2011; 121(6):2197-209. PMC: 3104746. DOI: 10.1172/JCI44774. View

18.

Nagai K, Matsubara T, Mima A, Sumi E, Kanamori H, Iehara N . Gas6 induces Akt/mTOR-mediated mesangial hypertrophy in diabetic nephropathy. Kidney Int. 2005; 68(2):552-61. DOI: 10.1111/j.1523-1755.2005.00433.x. View

19.

Dharnidharka V, Cherikh W, Abbott K . An OPTN analysis of national registry data on treatment of BK virus allograft nephropathy in the United States. Transplantation. 2009; 87(7):1019-26. DOI: 10.1097/TP.0b013e31819cc383. View

20.

Ekberg H, Tedesco-Silva H, Demirbas A, Vitko S, Nashan B, Gurkan A . Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007; 357(25):2562-75. DOI: 10.1056/NEJMoa067411. View